Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults

Human Vaccines

Volumn 3, Issue 5, 2007, Pages 205-211

  Campbell, James D ^a   Clement, Kristin H ^b   Wassermann, Steven S ^a,c   Donegan, Sarah ^d   Chrisley, Lisa ^a   Kotloff, Karen L ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

Anthrax; Clinical trial; Phase 1; Protective antigen; Vaccines

Indexed keywords

ANTHRAX VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ANTHRAX; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN;

EID: 35348941170     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.5.4459     Document Type: Article

References (19)

1. Ivins BE, Welkos SL. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 1988; 4:12-9.
2. Turnbull PC. Anthrax vaccines: Past, present and future. Vaccine 1991; 9:533-9.
3. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K. Anthrax as a biological weapon: Medical and public health management: Working Group on Civilian Biodefense. JAMA 1999; 281:1735-45.
4. Anthrax Vaccine Adsorbed (Bioport, Inc. Lansing Michigan) Package Insert. 1999.
5. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19:3241-7.
6. Brachman P, Gold H, Plotkin S, Fekety R, Werrin M, Ingraham N. Field evaluation of a human anthrax vaccine. American Journal of Public Health 1962; 52:632-45.
7. Use of anthrax vaccine in response to terrorism: Supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002; 51:1024-6.
8. Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, Goff JA, Rosenstein NE, Sever JL, McNeil MM. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis 2003; 37:905-11.
9. The Anthrax Vaccine. Is it Safe? Does It Work? In: Joellenbeck IM, Zwanziger LL, Durch JS, Strom BL, eds. Washington, DC: National Academy Press, Institute of Medicine, 2002.
10. Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986; 52:356-63.
11. Ivins BE, Welkos SL. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect Immun 1986; 54:537-42.
12. Hoch JA. Regulation of the phosphorelay and the initiation of sporulation in Bacillus subtilis. Annu Rev Microbiol 1993; 47:441-65.
13. Ribot WJ, Powell BS, Ivins BE, Little SF, Johnson WM, Hoover TA, Norris SL, Adamovicz JJ, Friedlander AM, Andrews GP. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine 2006; 24:3469-3476.
14. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson Jr GW, Gibbs PH, Friedlander AM. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998; 16:1141-8.
15. Worsham PL, Sowers MR. Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis. Can J Microbiol 1999; 45:1-8.
16. Quinn CP, Semenova VA, Elie CM, Romero-Steiner S, Greene C, Li H, Stamey K, Steward-Clark E, Schmidt DS, Motehrshed E, Pruckler J, Schwartz S, Benson RF, Helsel LO, Holder PF, Johnson SE, Kellum M, Messmer T, Thacker WL, Besser L, Plikaytis BD, Taylor Jr TH, Freeman AE, Wallace KJ, Dull P, Sejvar J, Bruce E, Moreno R, Schuchat A, Lingappa JR, Martin SK, Walls J, Bronsdon M, Carlone GM, Bajani-Ari M, Ashford DA, Stephens DS, Perkins BA. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002; 8:1103-10.
17. Hering D, Thompson W, Hewetson J, Little S, Norris S, Pace-Templeton J. Validation of the anthrax lethal toxin neutralization assay. Biologicals 2004; 32:17-27.
18. Little SF, Ivins BE, Fellows PF, Pirr ML, Norris SL, Andrews GP. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 2004; 22:422-30.
19. Gotse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kennet J, Deans L, Gurwith M. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial. Vaccine 2006; 24:5950-9.